ORIGINAL ARTICLE – Business Wire, March 17, 2022

Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced the completion of an extension of its Series A financing, bringing the total round to approximately $100 million. The Series A extension featured new investors, including significant participation from B Capital Group, along with ATEM Capital, the Myeloma Investment Fund, the Multiple Myeloma Research Foundation’s venture philanthropy subsidiary, and others, joined by significant participation from existing investors, Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures.

The proceeds of the financing will support the continued preclinical and clinical development of Triumvira’s T cell Antigen Coupler (TAC)-T cell therapy programs. Triumvira’s proprietary TAC receptor, a multi-domain chimeric molecule, interacts directly with the natural T cell receptor to uniquely help T cells recognize and eliminate tumor cells. The company’s lead program, TAC01-HER2, is currently being evaluated in a Phase 1/2 clinical trial for patients with HER2-overexpressing solid tumors (TACTIC-2), including breast, gastric, ovarian, pancreatic, gall bladder and non-small cell lung cancers.

To read the full article CLICK HERE.